Literature DB >> 9291418

Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen.

R Patterson1, E J Fitzsimons, A C Choy, K E Harris.   

Abstract

BACKGROUND: Malignant idiopathic anaphylaxis refers to the most severe form of idiopathic anaphylaxis where defined episodes of idiopathic anaphylaxis are not controlled when the prednisone is reduced below at least 60 mg every other day or 20 mg daily. Corticosteroid-dependent idiopathic anaphylaxis refers to patients with idiopathic anaphylaxis who require continuous daily or alternate day prednisone at threshold doses for control of idiopathic anaphylaxis. Ketotifen has been reported to help induce remission in some patients with idiopathic anaphylaxis and has steroid sparing effects in other patients with idiopathic anaphylaxis.
METHODS: We present five patients, two with malignant idiopathic anaphylaxis and three with corticosteroid-dependent idiopathic anaphylaxis, who responded to the administration of ketotifen.
RESULTS: All five patients, while receiving ketotifen, had a reduction or resolution of their episodes of idiopathic anaphylaxis and prednisone was tapered and discontinued.
CONCLUSION: Ketotifen is shown to be successful in inducing remission in two patients with malignant idiopathic anaphylaxis and in three additional patients with corticosteroid-dependent idiopathic anaphylaxis. An additional patient with malignant idiopathic anaphylaxis had prednisone stopped after elective hip surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291418     DOI: 10.1016/S1081-1206(10)63100-6

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  5 in total

Review 1.  Idiopathic anaphylaxis. The evolution of a disease.

Authors:  R Patterson
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Mast Cells and Anaphylaxis.

Authors:  Phil Lieberman; Lene Heise Garvey
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

3.  The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures.

Authors:  Michael J Monument; David A Hart; A Dean Befus; Paul T Salo; Mei Zhang; Kevin A Hildebrand
Journal:  J Bone Joint Surg Am       Date:  2010-06       Impact factor: 5.284

Review 4.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

5.  Type 1 Kounis syndrome in a patient with idiopathic anaphylaxis.

Authors:  Monica Sandhu; Jason Casselman; Brian Peppers; Haig Tcheurekdjian; Robert W Hostoffer
Journal:  Allergy Rhinol (Providence)       Date:  2017-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.